Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Difficulty finding eligible sites/patients:current situation in health policy cause negative effects on existing/planned contracts for integrated care programs
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| acromion GmbH | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All | Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Subjective Well-Being measured via SWN patient questionnaire | 6 month period of observation,4 assessments |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life and patient's satisfaction measured by Q-LES-Q-18 and CSQ-8 | 6 month period of observation, 1 assessment at end of NIS | |
| Symptomatic and functional outcome measured by CGI-S, PANSS-8, GAF, EQ-5D and VOI | 6 month period of observation, 4 assesments |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
outpatient department from clinics or private practices
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sandra Liedtke, MD | AstraZeneca | Study Director |
| Martin Lambert, PD, MD | University of Hamberg | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Ahrweiler | Germany | ||||
| Research Site |
Not provided
Not provided
Not provided
Not provided
| Compliance and health economic aspects measured by MARS, days of hospitalization, productivity loss | 6 month period of observation, 4 assesments |
| Berlin |
| Germany |
| Research Site | Bonn | Germany |
| Research Site | Hamburg | Germany |
| Research Site | Mannheim | Germany |
| Research Site | Mittweida | Germany |
| Research Site | München | Germany |
| Research Site | Münster | Germany |
| Research Site | Oldenburg | Germany |
| Research Site | Ottobrunn bei München | Germany |
| Research Site | Spremberg | Germany |
| Research Site | Stolberg | Germany |
| Research Site | Werneck | Germany |
| Research Site | Zittau | Germany |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D011618 | Psychotic Disorders |
| D012563 | Schizophrenia, Paranoid |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided